News
-
-
PRESS RELEASE
CLINUVEL: Record Half-Year Confirms Growth Trajectory – PARMANTIER & CIE. Presents Latest Research Study on CLINUVEL Pharmaceuticals' Half-Year Results
CLINUVEL Pharmaceuticals Ltd. reports record-breaking figures for H1 of fiscal year 2025, surpassing market expectations with strong revenue and EPS growth. Dr. Philippe Wolgen's leadership and strategic foresight driving sustainable success -
-
-
-
-
-
-
-